What factors drove the changes in Azenta's revenue and profit?

What is Azenta's latest dividend and current dividend yield?

What is the market's earnings forecast for Azenta next quarter?

What were the key takeaways from Azenta's earnings call?

What is Azenta's gross profit margin?

What is the revenue and EPS growth rate for Azenta year over year?

Did Azenta beat or miss consensus estimates last quarter?

What were the key takeaways from Azenta’s earnings call?

- **Organic Revenue Mixed**: 1% YoY decline overall, but Multiomics and Biorepositories grew despite macro challenges.
- **Margin Target Ambitious**: 300bps EBITDA expansion driven by North America recovery (200bps) and operational efficiency (100bps).
- **Quality Issues Resolving**: $3M-$5M Automated Stores costs to lapse by Q2, enabling margin rebound.
- **Strategic Moves**: B Medical sale and $250M share buyback enhance financial flexibility.
- **China Outperformance**: Multiomics up 26% organically, reflecting regional growth strategy success.

**【CEO Summary Section】**
- Organic revenue declined 1% YoY due to macroeconomic challenges, but Multiomics and Sample Management Solutions (SMS) segments showed growth.
- Emphasized operational excellence through the Azenta Business System (ABS), driving continuous improvement in efficiency and execution.
- Announced the sale of B Medical Systems, enhancing financial flexibility, and a $250M share repurchase authorization.
- Faced quality issues in Automated Stores, impacting margins, with expected resolution by Q2.
- Full-year 2026 guidance: 3-5% organic revenue growth and 300bps Adjusted EBITDA margin expansion.

**【CFO Financial Commentary】**
- Q1 2026 revenue: $149M (1% reported growth, 1% organic decline), with Multiomics and Biorepositories outperforming.
- Adjusted EBITDA margin: 8.5% (down 230bps YoY) due to gross margin pressures from underutilized labs and quality issues.
- $3M-$5M incremental costs from Automated Stores rework, expected to lapse in Q2.
- Free cash flow: $15M (Q1), supported by strong cash position of $571M.
- FY2026 targets: 3-5% organic growth, 300bps margin expansion, and >30% free cash flow improvement.

**【Q&A Highlights】**
- **Gross Margin Recovery**: CFO outlined 200bps from volume (North America rebound) and 100bps from ABS/automation, with $3M-$5M quality costs resolved by Q2.
- **North America Momentum**: CEO highlighted commercial reboot in Multiomics and SMS, with pharma/biotech demand driving second-half acceleration.
- **Academic Funding**: CFO noted cautious capital spending but optimism for second-half clarity on government funding.
- **Share Repurchases**: CFO reaffirmed commitment to disciplined capital deployment, with buybacks as a value-creation tool.
- **China Growth**: CFO highlighted 26% organic growth in Multiomics, driven by pharma/biotech investment and regional strategy success.

Azenta Inc (AZTA) Q1 2026 Earnings Call Transcript

- **2026 Growth Targets**: 3-5% core revenue growth, 300 basis points EBITDA margin expansion, and 30%+ free cash flow growth.
- **Segment Strength**: Multiomics NGS volume up 50% YoY in Q4, SMS C&I backlog conversion driving mid-single-digit growth.
- **Macroeconomic Resilience**: 310 basis points margin expansion in 2025 despite macro challenges, disciplined cost management to offset Q1 2026 CapEx softness.
- **Strategic Initiatives**: ABS-driven operational efficiency, $546 million cash balance for M&A and growth, and Investor Day in December to outline long-term strategy.

**【CEO Summary Section】**
- Fiscal 2025 revenue growth of 3% organically, with adjusted EBITDA margin expansion of 310 basis points, driven by operational efficiency and cost management.
- 2026 guidance: Core revenue growth of 3-5%, targeting 300 basis points of EBITDA margin expansion, and free cash flow growth over 30% year-over-year.
- Strategic focus on operational excellence through the Azenta Business System (ABS), reinvesting savings in growth initiatives, and disciplined capital allocation.
- Resilience in macroeconomic uncertainty, with opportunities in automation and digital workflows for customers seeking to do more with less.

**【CFO Financial Commentary】**
- Q4 2025 revenue: $159 million (6% YoY reported, 4% organic), with Multiomics delivering record $73 million (11% YoY reported, 10% organic) driven by Next Generation Sequencing (NGS) volume growth of 50% YoY.
- Full-year 2025 adjusted EBITDA margin: 11.2% (up 310 basis points YoY), with free cash flow of $38 million (up $26 million YoY).
- 2026 outlook: Low single-digit growth in Multiomics, mid-single-digit growth in SMS, and 300 basis points EBITDA margin expansion through operational leverage and cost discipline.

**【Q&A Highlights】**
- **Macroeconomic Impact**: Capital expenditure (CapEx) softness in Automated Stores and Cryo, partially offset by strength in pharma and biotech. Government shutdown delayed NIH funding approvals, impacting Q1 2026 revenue (-1% to -2% YoY).
- **Segment Performance**: Multiomics NGS normalization expected in 2026, while Plasmid-EZ growth offsets Sanger Sequencing decline. SMS C&I backlog conversion and SRS price optimization drive mid-single-digit growth.
- **M&A Strategy**: Focus on tuck-ins in Sample Repository Solutions (SRS), automated solutions, and synthesis to expand core capabilities.
- **Operational Momentum**: Strong balance sheet ($546 million cash) supports growth investments, with 2026 free cash flow expected to improve by over 30% YoY.

Azenta, Inc. (AZTA) Q4 2025 Earnings Call Transcript

- **Profitability Expansion**: Adjusted EBITDA margin up 260 basis points to 12.3%, with SMS gross margin improving 760 basis points to 53.6%.
- **Q4 Growth Catalysts**: $15 million step-up driven by delayed orders ($2M+ C&I), NGS momentum, and SMS backlog execution.
- **M&A Pipeline**: Robust tuck-in opportunities in biorepositories, automation, and Multiomics, with 2026 CAGR targets reaffirmed.
- **Cash Position**: $550M cash, no debt, supporting $11M capex for growth.

**【CEO Summary Section】**
- **Revenue Performance**: Organic revenue growth of 3% year-to-date, with Q3 revenue flat year-over-year at $144 million. Adjusted EBITDA margin expanded 260 basis points to 12.3%, driven by operational efficiency and cost discipline.
- **Strategic Initiatives**: Reaffirmed full-year 2025 guidance of 3-5% organic growth and 300 basis points EBITDA margin expansion. Emphasized M&A pipeline with focus on strategic tuck-ins and R&D investments to accelerate growth.
- **Customer Engagement**: Customer outreach initiative yielded direct feedback, leading to improved on-time delivery and service quality. Notable MSA with a core lab to reduce costs and improve service quality.
- **Financial Strength**: $550 million cash on hand, no debt, and $15 million free cash flow for the quarter. Strong balance sheet to support growth initiatives.

**【CFO Financial Commentary】**
- **Segment Performance**: 
  - **Sample Management Solutions (SMS)**: Revenue down 6% organically due to delayed capital equipment orders, but gross margin improved 760 basis points to 53.6% from favorable mix and cost management.
  - **Multiomics**: Revenue up 3% organically, driven by NGS growth (double-digit volume) and China expansion. Gross margin declined 500 basis points due to product mix and lower Sanger Sequencing volume.
- **Guidance**: Reaffirmed 3-5% organic growth and 300 basis points EBITDA margin expansion. Q4 expects $160 million revenue, requiring $15 million step-up from Q3, supported by order pushouts and improved execution.
- **Liquidity**: $550 million cash, $11 million capital expenditures for growth investments.

**【Q&A Highlights】**
- **Q4 Visibility**: $15 million step-up driven by delayed C&I orders ($2 million+), NGS momentum, and SMS backlog. CFO noted 2.5x revenue in C&I funnel, signaling pent-up demand.
- **M&A Strategy**: Focus on core extensions (biorepositories, automation) and Multiomics adjacencies. Pipeline robust with accretive opportunities expected in 2026.
- **NIH Funding**: 1% headwind for 2025, but Senate appropriations bill signals 1% NIH funding increase for 2026, potentially reducing headwind. Company well-positioned to benefit from outsourced research demand.
- **Execution Strength**: Improved on-time delivery in SMS, reduced accounts receivable, and weekly war room monitoring of macro risks (tariffs, funding delays).

Azenta (AZTA)-5 Aug 25-2025 Q3 Earnings call transcript

- **Revenue Resilience**: 6% organic growth vs. macro headwinds, with Multiomics and SMS both expanding margins.
- **Countermeasure Success**: 1% NIH funding risk neutralized, no EBITDA impact; tariffs mitigated through operational efficiency.
- **China Momentum**: Multiomics up 5% YoY, Plasmid-EZ revenue doubles YoY, offsetting Gene Synthesis decline.
- **Balance Sheet Strength**: $540M cash for M&A and buybacks, with $100M free cash flow target for 2025.

**【CEO Summary Section】**
- Q2 2025 organic revenue grew 6% YoY, driven by Multiomics (3% growth) and Sample Management Solutions (8% growth). Adjusted EBITDA margin expanded 400 basis points to 10%.
- Countermeasures to NIH funding cuts and tariffs mitigated a 1% revenue headwind, with near-zero EBITDA impact. China Multiomics revenue grew 5% YoY.
- Operational improvements include daily management boot camps, lean methodologies, and Kaizen events to reduce cycle times and improve quality.
- $540M cash balance supports potential tuck-in acquisitions and buybacks, with a focus on long-term value creation.

**【CFO Financial Commentary】**
- Q2 2025 revenue: $143M (5% YoY reported, 6% organic). Non-GAAP EPS: $0.05. Free cash flow: $7M, driven by working capital improvements.
- Multiomics gross margin: 44.9% (down 140bps YoY due to Gene Synthesis decline). Sample Management Solutions gross margin: 49.7% (up 340bps YoY).
- Full-year 2025 guidance: 3-5% organic revenue growth, 300bps EBITDA margin expansion. Free cash flow target: $100M.

**【Q&A Highlights】**
- **Macro Risks**: 1% NIH funding impact countermeasured; China tariffs and steel/aluminum tariffs mitigated through supply chain adjustments.
- **China Growth**: Multiomics revenue up 5% YoY, Gene Synthesis down 10% due to pharma delays, Plasmid-EZ revenue doubled YoY.
- **M&A & Buybacks**: Actively evaluating tuck-in acquisitions; open to buybacks if valuation disconnect persists.
- **Cash Position**: $540M cash, no debt, supporting strategic initiatives and shareholder returns.

Azenta, Inc. (AZTA) Q2 2025 Earnings Call Transcript

- **Revenue Beat**: Q1 2025 organic growth 4%, EBITDA margin +400bp to 9%, driven by SMS and Multiomics strength.
- **Strategic Wins**: $16M BioArc Ultra deal signals leadership in automated sample storage; Multiomics NGS up 11% YoY.
- **Profitability**: Non-GAAP EPS $0.08, gross margin +270bp to 47.6%. Free cash flow $22M, $530M cash on hand.
- **China Resilience**: NGS 7-10% of Multiomics, insulated from tariffs via BGI partnerships. Gene Synthesis stable at mid-single digits.
- **2025 Outlook**: 3-5% revenue growth, 300bp EBITDA expansion. Share buybacks deprioritized in favor of operational excellence and M&A.

**【CEO Opening Remarks】**
- **Revenue Growth**: Q1 2025 organic revenue grew 4% YoY, driven by strong performance in both Sample Management Solutions (SMS) and Multiomics businesses. Adjusted EBITDA margin expanded by 400 basis points to 9%.
- **Strategic Focus**: Emphasized three key priorities: portfolio optimization (including B Medical Systems sale), operational excellence (e.g., business system implementation, Kaizen events), and value-enhancing capital allocation.
- **Customer Wins**: Highlighted the $16 million BioArc Ultra order with U.K. Biocentre, showcasing leadership in high-density automated storage.
- **Guidance**: Reiterated full-year 2025 targets of 3-5% organic revenue growth and 300 basis points EBITDA margin expansion.

**【CFO Financial Highlights】**
- **Topline**: Q1 revenue $148 million (+4% YoY), with SMS and Multiomics both contributing growth. Multiomics NGS revenue up 11% YoY, China Multiomics up 7%.
- **Profitability**: Non-GAAP EPS $0.08, driven by 270bp gross margin improvement (47.6%) and 400bp EBITDA margin expansion. Free cash flow $22 million.
- **Segment Breakdown**: SMS revenue $81 million (+3% YoY), Multiomics $66 million (+6% YoY). SMS gross margin 47.8% (up 460bp YoY).
- **Balance Sheet**: $530 million cash, no debt. Capital expenditures $8 million (70% growth-focused).

**【Q&A Key Themes】**
1. **BioArc Ultra Impact**: U.K. Biocentre deal (~$16M) in Q1, operational in early 2026. Management expects similar wins in biopharma and research sectors.
2. **China Market Risks**: NGS business ~7-10% of Multiomics, insulated from Illumina tariffs via BGI partnerships. Gene Synthesis stable at mid-single digits.
3. **Margins & Restructuring**: Q1 EBITDA 9% (excluding one-time costs >10%). G&A reduction ($17M restructuring) offset by R&D/sales reinvestment. 2025 EBITDA target on track.
4. **Multiomics Growth**: NGS price stabilization, Sanger Sequencing decline offset by ONT Plasmid-EZ growth (~300% YoY). 2025 Multiomics low-single-digit growth expected.
5. **M&A Outlook**: Share buybacks last priority; focus on gross margin improvement, organic growth, and tuck-in acquisitions post-2026.


Actual											0.25	0.32	0.47	0.47	0.61	0.72	0.12	0.12	0.12	0.12	0.16	0.12	-0.06	0.13	0.13	0.02	0.05	0.16	0.18	0.08	0.05	0.19	0.21	0.09
Forecast											0.249	0.2183	0.3565	0.4183	0.505	0.689	0.7655	0.0775	0.1117	0.08	0.066	0.0991	-0.022	-0.026	0.0183	-0.034	0.0237	0.0814	0.1025	0.0571	0.07	0.1363	0.1895	0.1381
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+0.40%	+46.59%	+31.84%	+12.36%	+20.79%	+4.50%	-84.32%	+54.84%	+7.43%	+50.00%	+142.42%	+21.09%	-172.73%	+600.00%	+610.38%	+158.82%	+110.97%	+96.56%	+75.61%	+40.11%	-28.57%	+39.40%	+10.82%	-34.83%

AZTA

AZTA fundamentals

AZTA Q1 2026 Earnings

Earnings Call

You can ask Aime

AZTA

AZTA fundamentals

AZTA Q1 2026 Earnings

Earnings Call

AZTA Earnings Call Summary for Q1/20268:30 AM on Feb 4, 2026

AZTA Earnings Call Summary for Q4/20258:30 AM on Nov 21, 2025

AZTA Earnings Call Summary for Q3/20258:30 AM on Aug 5, 2025

AZTA Earnings Call Summary for Q2/20258:30 AM on May 7, 2025

AZTA Earnings Call Summary for Q1/20258:30 AM on Feb 5, 2025

You can ask Aime